Publication Name	World Journal of Gastroenterology
Manuscript ID	90838
Country	Italy

Received	2023-12-15 07:22
Peer-Review Started	2023-12-15 07:22
To Make the First Decision
Return for Revision	2024-01-04 09:21
Revised	2024-01-11 18:59
Second Decision	2024-02-18 01:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-18 02:49
Articles in Press	2024-02-18 02:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-02-26 05:52
Publish the Manuscript Online	2024-03-06 06:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo and Stella De Nicola
ORCID	Author(s) ORCID Number Francesca Colapietro http://orcid.org/0000-0002-7520-744X Nicola Pugliese http://orcid.org/0000-0001-6466-1412 Alessio Aghemo http://orcid.org/0000-0003-0941-3226
Funding Agency and Grant Number
Corresponding Author	Francesca Colapietro, MD, Doctor, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Milan 20072, Italy. francesca.colapietro@humanitas.it
Key Words	Chronic hepatitis B; Reactivation; Nucleoside analogue; Tyrosine kinase inhibitors; Onco-hematology
Core Tip	Hepatitis B virus reactivation (HBVr) is a clinical challenge among patients receiving chemotherapy for solid tumors or hematologic malignancies. The emergence of novel immunosuppressive and immunomodulatory agents requires expertise in delineating the risk of HBVr associated with each drug class. Classifying the risk of HBVr into low (< 1%), intermediate (1%-10%) and high (> 10%) allows physicians to understand in whom nucleos(t)ide analogues (NAs) are required to avoid potential progression to liver failure and death. To note, according to guidelines, patients without immediate indication for NAs should undergo serial monitoring of blood test for transaminases and HBV profile, including hepatitis B surface antigen status and HBV-DNA titer.
Publish Date	2024-03-06 06:10
Citation	Colapietro F, Pugliese N, Voza A, Aghemo A, De Nicola S. Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis. World J Gastroenterol 2024; 30(9): 1253-1256
URL	https://www.wjgnet.com/1007-9327/full/v30/i9/1253.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i9.1253

Full Article (PDF)	WJG-30-1253-with-cover.pdf
Manuscript File	90838_Auto_Edited-YJP.docx
Answering Reviewers	90838-Answering reviewers.pdf
Audio Core Tip	90838-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90838-Conflict-of-interest statement.pdf
Copyright License Agreement	90838-Copyright license agreement.pdf
Peer-review Report	90838-Peer-review(s).pdf
Scientific Misconduct Check	90838-Bing-Wang JJ-2.png
Scientific Editor Work List	90838-Scientific editor work list.pdf